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Abstract 
Background: Focal segmental glomerulosclerosis (FSGS) is a major cause of renal failure. Sera of some FSGS patients 
increase glomerular albumin permeability (Palb) during in vitro testing and cause proteinuria in experimental animals.
Objectives: To determine whether permeability activity of FSGS serum (Palb activity) is associated with rate of pro-
gression to renal replacement therapy (RRT).
Design: This is an observational study based on medical and demographic information and Palb activity testing.
Setting: Studies were performed at Medical College of Wisconsin.
Patients: Serum was submitted by patients’ nephrologists for measurement of Palb activity. Each patient had had a 
biopsy diagnosis of FSGS, had reached ESRD and was on dialysis or had a functioning transplant.
Measurements: Palb activity, clinical characteristics and time between biopsy diagnosis and RRT (T-RRT) were 
recorded for each patient.
Methods: Palb activity was measured using established in vitro techniques.
Results: Palb and T-RRT were inversely correlated. Neither Palb nor T-RRT varied with demographics or medications. 
Kaplan–Meier survival curves showed that patients with Palb ≥ 0.5 progressed to RRT more rapidly than others.
Limitations: Only patients who had reached RRT were included. Limited clinical information was available for each 
patient. Central verification of biopsy characteristics was not performed and detailed descriptions of renal histology 
were not available.
Conclusions: Palb activity is associated with the rate of progression to RRT in patients with FSGS. Additional observa-
tions will be needed to verify that Palb activity predicts prognosis and is useful in stratifying patients for clinical deci-
sion making or treatment trials.
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Background
Focal segmental glomerulosclerosis (FSGS) is charac-
terized by nephrotic-range proteinuria and a distinctive 
histopathological appearance on biopsy. FSGS accounts 
for a third of primary nephrotic syndrome in adults and 
a quarter in children. The etiology of FSGS is unknown 
in the majority of cases, but can be secondary to genetic 
abnormalities, decreased nephron number, hyperperfu-
sion/hyperfiltration, reflux nephropathy, obesity, viral 
infections, drugs and malignancy (Daskalakis and Winn 
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2006; D’Agati et  al. 2011). The lesion in FSGS is pro-
gressive and leads to a need for renal replacement ther-
apy (RRT) in 50–75 % of patients over a 10-year period 
(Braun et al. 2008; Korbet 2012; Franceschini et al. 2003; 
Burgess 1999). In a subset of patients with FSGS, the pro-
gression to RRT is rapid and progression to end-stage 
renal disease occurs within 3 years. A measure by which 
one could identify patients who are at high risk for rapid 
progression to RRT would allow modification of the 
approach to therapy for the individual patient. In addi-
tion, a tool to identify these subjects would be valuable in 
designing and interpreting clinical trials on FSGS.
We have developed albumin permeability (Palb) testing 
as a functional assay to provide a sensitive measure of the 
integrity of the glomerular macromolecular permeability 
barrier. Experimental values for Palb activity vary from 0, 
normal, to 1.0, representing maximal loss of barrier func-
tion (Savin et al. 1992). We have used this test to deter-
mine the effect of patient serum on glomerular barrier 
function. We have shown increased permeability activity 
(Palb activity or Palb) in samples of serum or plasma from 
renal transplant recipients with recurrent FSGS (Cattran 
et  al. 2003; Savin et  al. 2008). Palb activity is stable over 
time (Cattran et al. 2003; Savin et al. 1996, 2008) and is 
not affected by treatment with cyclosporine even when 
there is remission of nephrotic syndrome and is dimin-
ished by plasmapheresis (Savin et al. 1996). The injurious 
effect of serum as well as the occurrence of proteinuria in 
experimental animals after injection of serum, plasma or 
plasma fractions, and remission of post-transplant pro-
teinuria after plasmapheresis or immunoadsorbtion has 
led us to hypothesize that a circulating factor is respon-
sible for recurrence of FSGS in allografts (Savin et  al. 
1996; Sharma et al. 2002, 2004a, b; McCarthy et al. 2010; 
Zimmerman 1984). The aim of the current study was 
to determine if high Palb activity in patients with FSGS 




Albumin permeability (Palb) activity was determined 
using serum samples submitted to the Center for Glo-
merular Pathophysiology at the Medical College of Wis-
consin in the course of clinical evaluation of FSGS. All 
research activities were approved by the Human Subjects 
Committee of the Medical College of Wisconsin and 
were in compliance with the Helsinki Declaration. Sam-
ples were frozen at the site of collection and shipped to 
the study site by overnight carrier and remained frozen 
until they were thawed for analyses. Samples submit-
ted from January 2001 through December 2004 were 
included. Inclusion criteria were diagnosis of primary 
FSGS as indicated on renal biopsy report, progression to 
renal replacement therapy (RRT) and availability of data 
including patient demographics, laboratory data, renal 
biopsy diagnosis, date of renal biopsy, date of initiation of 
dialysis or transplant and medications prescribed at the 
time the serum specimen was collected. Data regarding 
the duration of symptoms and information about medi-
cal therapy given prior to serum sample collection were 
not available. Patients with incomplete data and those 
who had not progressed to RRT were excluded. Values 
from samples obtained after plasmapheresis therapy 
were excluded because we have shown that this therapy 
decreases Palb activity (Savin et al. 1996). No information 
regarding renal function at the time of the biopsy, reason 
for performing the biopsy, details of renal histology, or 
classification of the pattern of FSGS was available. Time 
to renal replacement therapy (T-RRT) was defined as the 
duration between the date of biopsy diagnosis of FSGS to 
one of the following: (a) the date of initiation of dialysis, 
(b) the date of renal transplantation or (c) the date when 
GFR was <15 ml/min as estimated by MDRD formula for 
adults and Schwartz formula for children. Rapid progres-
sion was defined as the progression to RRT within 3 years 
of diagnosis. This cut-off was chosen because it is com-
monly used in the pediatric literature as a parameter 
associated with high risk for post-transplant recurrence 
(Artero et al. 1994).
Albumin permeability (Palb) assay
Palb is a continuous dimensionless variable that ranges 
from 0 to 1. Palb testing was carried out under standard 
conditions (Savin et  al. 1992, 1996). Briefly, glomeruli 
were isolated from the renal cortex of normal rats. Iso-
lation/incubation medium was isotonic and contained 
bovine albumin, 5 gm/dl, as an oncotic agent. Glomeruli 
were incubated for 10 min at 37 °C in medium to which 
patient serum, 2  % vol/vol, had been added or in con-
trol medium. Palb was calculated as previously described 
(Sharma et al. 2000). In the current study, Palb activity of 
≥0.5 was used to define high activity. This cutoff value 
is consistent with our practice for interpretation of val-
ues for individual patients and is the 95  % confidence 
limit for values from normal serum or sera of patients 
with non-glomerular disease (Savin et al. 1996). We per-
formed additional analyses in which patients were strati-
fied using Palb activity of ≥0.4 to ≥0.7. All measurements 
were carried out without knowledge of the sample being 
tested and both positive and negative control samples 
were tested in each assay.
Statistical analyses
Continuous variables were summarized as mean  ±  SD. 
Univariate correlations were evaluated using Pearson 
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correlation analysis. Group comparisons were performed 
using Student’s t test. The Chi squared test was used to 
investigate changes in proportion of categorical vari-
ables. Odds ratio was used to measure the association of 
Palb with T-RRT. Renal survival was investigated using 
Kaplan–Meier survival curves stratified by time com-
pared between groups using the log-rank test. In addi-
tion, a latent class regression model was fitted to the data 
to detect heterogeneity of associations between Palb and 
T-RRT. Statistical analysis was performed using SPSS 
20.0 software (SPSS Inc., Chicago, IL) and SAS version 




A total of 103 serum samples were submitted during 
the period studied. Of these, 87 were from patients with 
FSGS. The others were from patients in whom no biopsy 
report was available or who had other proteinuric renal 
diseases. Complete data was available for 80 samples; 
these were included in further analysis. Palb activity aver-
aged 0.58 ± 0.25 (mean ± SD, n = 80, range 0.05–0.98) 
with a median of 0.52. Patients’ age ranged from 1 to 
63 years; 35 (44 %) were male, 53 (66 %) were Caucasian, 
21 (26 %) were African-American, 5 (6 %) were Hispanic 
and 1 (1  %) Asian. Average T-RRT was 3.2 ±  3.3  years 
(n = 80, range 0–14.5 years). At the time of sample col-
lection, 25  % were receiving angiotensin converting 
enzyme inhibitors (ACE-I), 11  % angiotensin receptor 
blockers (ARB) and 16  % statin therapy (Table  1). Six-
teen percent were receiving steroids, 5  % cyclosporine. 
Eighteen patients had been transplanted, 6 had experi-
enced recurrence and 4 had lost allografts. Seven of the 
transplanted patients were not on immunosuppression 
at the time of the sample; each of these patients had fail-
ing allografts or had lost prior allografts. All patients who 
experienced FSGS recurrence had Palb activity ≥0.5.
Relationships between Palb activity and T‑RRT in FSGS
Forty-six patients (57.5  %) required RRT within 3  years 
after renal biopsy. Palb activity in these patients was 
significantly higher than in patients who had a longer 
course to RRT (0.63 ± 0.22 vs. 0.50 ± 0.28, p = 0.025). 
In patients with T-RRT > 3 months, there was a signifi-
cant inverse correlation between Palb activity and T-RRT 
described by the equation T-RRT  =  7.10  −  4.96*Palb 
(Pearson correlation coefficient r  =  −0.27, p  =  0.016). 
Palb activity was the only significant predictor for T-RRT. 
There was no effect of age, gender or ethnicity (propor-
tional hazards model). The frequency distribution of Palb 
activity ≥0.5 and T-RRT was calculated in order to fur-
ther examine the association between Palb activity and 
T-RRT. Results are shown in Fig. 1. Associations were as 
follows: Thirty-seven patients had T-RRT  <  3  years and 
Palb ≥ 0.5, 9 had T-RRT < 3 years and Palb activity <0.5, 
18 had T-RRT ≥ 3 years and Palb activity ≥0.5 and 16 had 
T-RRT  ≥  3  years and Palb activity <0.5. The odds ratio 
was calculated for T-RRT < 3 years in patients with Palb 
activity ≥0.5 was 3.65 (95 % CI of 1.36–9.86). Chi square 
test showed a significant difference on T-RRT < 3 years 
between low and high Palb activity groups (36.0 vs. 67.3 %, 
respectively, p = 0.009). There were no significant differ-
ences in Palb between Caucasians and African-Americans 
Table 1 Patient characteristics
Number of patients in each category is as indicated. Percentages are calculated according to the number in each Palb or T-RRT category
There were no statistically significant differences between patients with Palb < 0.5 and those with higher values nor were there differences between those with 
T-RRT < 3 years and those with a longer course
All patients Stratified by Palb Stratified by T‑RRT




T-RRT < 3 years
45
T-RRT > 3 years
35
Age (years) 30.1 ± 17.2 29.7 ± 19.6 30.2 ± 16.2 30.3 ± 17.0 30.62 ± 16.7
Male gender, n (%) 35 (44) 10 (40) 25 (45) 20 (44) 15 (43)
Ethnicity, n (%)
 Caucasian 53 (66) 17 (68) 36 (65) 26 (47) 27 (76)
 African American 21 (26) 6 (24) 15 (27) 15 (33) 6 (17)
 Other 7 (9) 2 (8) 5 (9) 1 (0.4) 6 (13)
Medications, n (%)
 ACEI and/or ARB 25 (31) 7 (28) 18 (33) 15 (33) 10 (28)
 Steroids 13 (16) 1 (4) 12 (21) 7 (16) 6 (17)
 Cyclosporine or tacrolimus 4 (5) 1 (4) 3 (5) 7 (16) 6 (17)
 Statins 13 (16) 3 (12) 10 (18) 9 (20) 4 (11)
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(p = 0.76) or between genders (p = 0.64). Palb activity did 
not vary significantly with medications, age, gender or 
ethnicity as covariates in a linear regression model.
Kaplan–Meier survival curves showed that patients who 
had Palb  ≥  0.5 progressed to renal replacement therapy 
more rapidly than others by log rank (Mantel–Cox) test 
(p  =  0.009). The Kaplan–Meier curves displayed here 
were generated using only samples from patients (n = 66) 
in whom T-RRT was >3  months (Fig.  2). This decision 
was made on the basis of the latent class regression model 
described below. Note that the survival diverged after 1 year 
and that by 4 years, survival was more than double in the 
group with low Palb activity versus those with high Palb activ-
ity. Differences in the Kaplan–Meier survival curves were 
also significant for Palb ≥ 0.4 (p = 0.01) and Palb activity ≥0.6 
(p = 0.012), but not for a Palb activity cut-off ≥0.7 (data not 
shown). Thus, Palb activity discriminated between patients 
with FSGS who did or did not have T-RRT within 3 years. 
At a cut-off for Palb activity of ≥0.5, the sensitivity and speci-
ficity were 80.4 and 47.1  %, respectively. The positive and 
negative predictive values were 67.3 and 64.0 %, respectively.
Latent class regression model
A latent class regression model for associations between 
Palb and T-RRT was applied and 2 distinct patterns were 
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Fig. 1 Depiction of the relationship between Palb activity and T-RRT 
for patients with Palb ≥ 0.5 and Palb < 0.5 (n = 80). Black bars indicate 
patients in whom T-RRT was less than 3 years. Hatched bars indicate 
patients in whom T-RRT was 3 years or greater. P = 0.009, Chi square 
test, as described in the text. The odds ratio for T-RRT < 3 years in 
patients with Palb activity ≥0.5 was 3.65 (95 % CI of 1.36–9.86)
Fig. 2 Kaplan–Meier survival curve. Patients with focal segmental glomerulosclerosis (FSGS) were stratified by albumin permeability (Palb) ≥0.5 
(solid line) and Palb < 0.5 (dashed line). Kaplan–Meier survival curve showed that patients with who had Palb ≥ 0.5 progressed to RRT more rapidly. 
Patients with calculated T-RRT < 3 months (0.25 years) were excluded from this analysis (see text in “Results” section, “latent class regression model” 
for the rationale for this exclusion)
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patients had advanced CKD at the time of biopsy as 
indicated by high serum creatinine. Palb activity was not 
significantly associated with T-RRT. In the remaining 
66 subjects, in whom biopsies showing FSGS were per-
formed when the GFR was higher, there was an inverse 
association between Palb and T-RRT described by the fit-
ted regression equation, T-RRT = 7.10 − 4.96*Palb.
Discussion
The clinical course in adults with primary FSGS is vari-
able, with about half of adults progressing to RRT in 
10  years (Braun et  al. 2008; Korbet 2012; Franceschini 
et al. 2003; Burgess 1999). Currently, there is no good his-
tological or biochemical marker that predicts outcome 
in FSGS. Histological variants have been described and 
attempts have been made to use histological classification 
to predict response to therapy and prognosis (Schwartz 
et  al. 1999; Thomas et  al. 2006; Chun et  al. 2004; Bari-
soni 2012). The collapsing variant shows a more rapid 
progression compared to other histological classes but 
other histological variants including tip lesion do not 
predict either response to treatment or prognosis (Valeri 
et al. 1996; Detwiler et al. 1994; Couser 2005). The treat-
ment of primary FSGS is based on the rationale that a 
humoral factor or factors derived from a dysregulated 
immune system are responsible for development of pro-
teinuria. At present, the majority of therapeutic inter-
ventions depends on corticosteroids or other traditional 
immunosuppressive agents and is associated with a range 
of side-effects (Braun et  al. 2008; Korbet 2012). Recent 
studies indicate that cyclosporine and mycophenolate 
mofetil each induce remission in some steroid resistant 
patients (Hogg et al. 2013). Other novel agents including 
adalimumab (anti-TNF alpha), galactose and a novel dual 
endothelin receptor blocker and angiotensin receptor 
blocker (DUET trial, Sparsentan) are in trials (Joy et  al. 
2010; Trachtman et al. 2011a, b, 2015). A biomarker that 
could be used to stratify FSGS patients according to risk 
for rapid progression would be useful in design and inter-
pretation of such trials. Such a biomarker might eventu-
ally allow individualization of therapy according to the 
potential risks and benefit.
Strengths of this study include the fact that our unique 
sample included FSGS patients who had reached RRT 
at the time of testing for Palb. All FSGS patients whose 
samples we analyzed were included; there were no cen-
sored observations. Patients represented a wide range 
of rates of progression and included both genders, and 
included both children and adults as well as several eth-
nicities. However, the study has several limitations. First, 
the dataset was limited to a cohort of FSGS patients 
who had progressed to RRT. We did not include samples 
from patients who continued to have adequate GFRs at 
the time the sample was submitted. We had only limited 
information regarding the patients’ prior history. Our 
information regarding medications was limited to their 
current therapy at the time of serum sample. We col-
lected the information regarding current medications to 
examine potential interference with the Palb activity assay. 
No other information about their treatment during the 
course of disease was available but it is likely that many 
patients had received corticosteroids. The low rates of 
immunosuppressive therapy may have reflected the fact 
that the majority had reached ESRD and were no longer 
on therapy directed at treatment of FSGS or nephrotic 
syndrome while others may never have received therapy. 
The small size of the sample does not permit analysis of 
potential medication effects but our prior work indicates 
that cyclosporine does not alter Palb (Cattran et al. 2003). 
An additional limitation arises from the fact that the 
sample may reflect referral bias as it relates to submission 
of the sample for Palb testing. The sample may include 
a disproportionate number of patients who had good 
access to health care and to physicians who were aware 
of the potential for Palb testing. It may also over-represent 
patients with prior post-transplant recurrence or those 
who are awaiting initial renal transplants.
We have used Palb to follow activity of plasma dur-
ing sequential fractionation and to characterize the cir-
culating permeability factor for recurrence of FSGS in 
allografts. The central role for a circulating permeability 
factor in FSGS is based on the observations of (a) early 
recurrence of nephrotic syndrome after transplanta-
tion, (b) development of albuminuria in rats after injec-
tion of serum from these patients, (c) response to plasma 
exchange and (d) occurrence of transient proteinuria 
in infants born to women with FSGS (Savin et  al. 1996; 
Sharma et al. 2002, 2004a, b; McCarthy et al. 2010; Zim-
merman 1984; Gohh et  al. 2005; Kemper et  al. 2001). 
We have described the circulating permeability factor 
as a hydrophobic sialoprotein with a molecular weight 
in the range of 30 kDa. It binds to galactose coated aga-
rose beads and can be eluted using a galactose solution 
(Sharma et al. 2004a). We have used mass spectrometry 
to identify cardiotrophin-like cytokine factor-1 (CLCF-1) 
in active fractions and have shown that glomerular and 
podocyte responses to CLCF-1 parallel the responses to 
FSGS serum (McCarthy et al. 2010; Sharma et al. 2015). 
Another candidate for the FSGS “factor” has been iden-
tified by Wei and colleagues. They have reported that 
increased concentrations of soluble urokinase-type plas-
minogen activator receptor (suPAR) are present in FSGS 
plasma and propose that suPAR concentration predicts 
post-transplant recurrence (Wei et  al. 2011). Additional 
molecules including hemopexin, angiopoietin-like-4 and 
CD80 are associated with nephrotic syndrome and have 
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also been shown to cause proteinuria in experimental 
animals (Garin et  al. 2010; Lennon et  al. 2008; Clement 
et al. 2011) but do not appear to be relevant to FSGS. The 
severity of nephrotic syndrome or FSGS is generally clas-
sified as “steroid sensitive”, “steroid resistant” or “steroid 
dependent” and according to the response to cytotoxic 
or immunosuppressive agents. These categories are nec-
essarily applied only post hoc and cannot be used to 
guide initial treatment. Likewise, even within categories 
defined by response to therapy, there is no clear associa-
tion between clinical parameters and progression of renal 
failure. There are no reports of a quantitative method for 
stratifying risk of rapid progression to RRT.
We have proposed that Palb activity ≥0.5 reflects the 
presence of a high concentration of circulating permea-
bility factor(s) which causes significant glomerular injury 
and rapid progression in FSGS. Palb activity was ≥0.5 in 
38 % of 26 children with newly diagnosed nephrotic syn-
drome 2 of whom were later diagnosed with FSGS. In 
that sample, Palb but did not differ between steroid sen-
sitive and steroid resistant patients (Trachtman et  al. 
2004). We have found Palb activity ≥0.5 in 20–38  % in 
additional cohorts of FSGS (Savin et  al. 1996; Tracht-
man et al. 2004). We previously reported that patients in 
whom FSGS recurred after transplantation had a higher 
Palb (0.47 ± 0.06) compared to that of FSGS patients who 
did not recur (0.14 ± 0.06). A Palb value of 0.5 permitted 
risk stratification, with 86  % of patients with Palb value 
of ≥0.5 developing recurrence versus only 17  % with 
Palb  <  0.5 (Savin et  al. 1996). In an independent sample 
of patients awaiting transplantation, Palb was greater than 
0.6 in 9 of 10 patients with prior recurrence or rapid pro-
gression to ESRD (mean Palb 0.76 ± 0.21, n = 10) (Gohh 
et al. 2005). Testing Palb activity is currently available on a 
limited scale in our laboratory. It may provide an oppor-
tunity to evaluate FSGS patients using a non-invasive 
test. Measurement of a single molecule in the circulation 
may eventually supplant this functional assay, but the 
identity of active molecules in FSGS is currently being 
debated. In addition, any specific assay will risk missing a 
previously unidentified injurious molecule. The Palb assay 
may be a valuable tool both in designing and interpreting 
clinical research trials on FSGS. Prospective validation of 
our findings in a trial with defined selection criteria will 
be required prior to the general use of Palb activity for 
establishing prognosis in patients with FSGS.
 In summary, our results indicate that high Palb activ-
ity is associated with rapid progression to RRT in biopsy 
proven FSGS. We suggest that Palb activity may be useful 
for risk stratification in future clinical trials of aggressive 
therapy or novel therapy in FSGS. Further studies will be 
required before Palb activity can be used to provide spe-
cific prognosis or dictate therapy in individual patients.
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